Benzinga | Aug 4, 2020 04:08PM EDT

Rigel Pharmaceuticals Q2 EPS $(0.10) Beats $(0.13) Estimate, Sales $16.02M Beat $13.75M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $16.02 million which beat the analyst consensus estimate of $13.75 million by 16.52 percent. This is a 53.94 percent increase over sales of $10.41 million the same period last year.